1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
NovMetaPharma Co., Ltd.

NovMetaPharma Co., Ltd.

KKRX:229500
3,680.00
KRW
+80.00
(+2.22%)
-1,271.91EPS
343.27BMarket Cap
NovMetaPharma Co., Ltd.
KRX:229500
(Korea Stock Exchange)

Recent

price

3,680.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
KRW
230.65
374.19
98.99
102.91
16.19
4.94
8.31
3.29
1.32
4.07
2.92
- -
Revenue per Share
-179.26
-531
-767
-1,519
-1,402
-736
-787.44
-638
-1,201
-504
-874.4
-1,257.37
Basic EPS, GAAP
-268.5
-451.33
-660.83
-1,211.14
-1,374.94
-582.22
-547.38
-427.91
-536.05
-464.92
-287.83
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
1,276.84
797.56
1,482.64
370.69
408.62
55.48
-452.54
-435.77
502.45
155.31
282.67
178.67
Book Value per Share
1,246.6
739.74
1,418.91
297.11
337.18
-52.68
-595.77
-570.06
373.29
18.25
146.27
83.94
Tangible Book Value per Share
7
8
8
9
9
9
9
10
10
11
12
9
Basic Weighted Avg Shares
1,574
2,908
784
891
143
44
74
31
14
45
35
- -
Sales/Revenue/Turnover
-81.37
-146.21
-702.74
-1,510.71
-8,769.54
-14,855.36
-9,264.14
-23,683.66
-56,128.86
-12,226.75
-15,405.9
- -
Operating Margin (%)
60
78
85
100
255
259
241
260
255
275
290
253
Depreciation Expense
-1,223
-4,126
-6,076
-13,146
-12,377
-6,597
-7,058
-6,111
-12,555
-5,605
-10,448
-11,205
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-77.72
-141.91
-774.83
-1,476
-8,658.12
-14,890.92
-9,475.49
-19,410.94
-90,646.44
-12,368.2
-29,988.86
- -
Profit Margin (%)
8,698
4,819
11,875
3,387
3,573
3,262
-2,112
-6,013
3,501
-1,020
565
1,278
Working Capital
- -
- -
- -
- -
82
291
209
94
76
140
33
- -
LT Debt
9,929
6,202
12,833
4,337
4,638
4,575
-463
-4,238
5,572
1,757
3,593
2,525
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-51.16
-63.84
-163.9
-360.29
-317.21
- -
- -
- -
-152.95
-390.62
- -
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Sep'19
Dec'19
Jun'20
ST Debt
- -
98
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
191
82
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
9
9
9
Market Capitalization
381,813
376,436
343,273

Working Capital

KRW

•

in mil. unless spec.
Sep'19
Dec'19
Jun'20
Total Current Assets
7,476
4,350
1,763
Cash, Cash Equivalents & STI
6,944
3,881
1,478
Accounts Receivable, Net
- -
- -
- -
Inventories
64
44
30
Total Current Liabilities
1,090
777
485
Payables & Accruals
- -
- -
- -
ST Debt
- -
98
- -
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
51.93%
102.11%
104.52%
Free Cash Flow
17.28%
-5.39%
-33.48%
Net Income, GAAP
47.85%
26.02%
86.41%
Sales/Revenue/Turnover
3.08%
31.69%
-23.12%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
14
2024
- -
- -
- -
- -
45
2025
- -
- -
- -
- -
35

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-1,201
2024
- -
- -
- -
- -
-504
2025
- -
- -
- -
- -
-874.4

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
NovMetaPharma Co., Ltd. is a South Korea-based biopharmaceutical and biotechnology company primarily engaged in the research, development, and commercialization of therapeutic treatments for metabolic, chronic, and degenerative diseases. Founded in 2010 and headquartered in Seoul, South Korea, the company operates across the biopharmaceutical, functional food, and veterinary healthcare sectors. The company develops proprietary pharmaceutical candidates based on endogenous metabolic regulatory substances and peptide technologies. Its primary clinical pipeline and product portfolio include Nov-DB (NV-201), a therapeutic candidate designed for the treatment of Type 2 diabetes mellitus by improving insulin sensitivity and blood glucose regulation; Nov-OB (NV-202), an anti-obesity and metabolic syndrome treatment candidate; Nov-ND (NV-203), a therapeutic targeted at diabetic nephropathy and chronic kidney disease; Nov-AD (NV-204), a developmental drug candidate for Alzheimer's disease and neurodegenerative disorders; Nov-PD, a pre-clinical therapeutic candidate for Parkinson's disease; functional dietary supplements and health foods formulated with proprietary bioactive metabolic modulators to support glucose and weight management; dermocosmetic and skincare formulations; and veterinary health products for companion animals. NovMetaPharma has implemented several strategic initiatives and operational adjustments to expand its commercial footprint and advance its clinical pipeline. The company has progressed United States Food and Drug Administration (FDA) Phase 2 clinical trials for its flagship diabetes and diabetic nephropathy candidates while expanding its global intellectual property portfolio across North America, Europe, and East Asia. To enhance revenue generation alongside its long-term pharmaceutical research, the company has expanded its commercial operations into functional health foods, consumer healthcare products, and pet care formulations. Furthermore, NovMetaPharma has entered into strategic research partnerships and supply agreements with domestic and international partners, while restructuring its capital and corporate development strategy to support clinical milestone execution and pursue listing relocation initiatives on the Korea Exchange.